Bioorganic and Medicinal Chemistry Letters p. 3213 - 3215 (2016)
Update date:2022-08-11
Topics:
Kim, Hyungmi
Kim, Mi Kyoung
Choo, Hyunah
Chong, Youhoon
The previously identified Janus kinase 1 (JAK1)-selective inhibitor, 1-(2-aminoethyl)-2-(piperidin-4-yl)-1H-benzo[d]imidazole-5-carboxamide (2), suffered from low cell permeability, which resulted in poor pharmacokinetic properties. In this study, by introducing less polar hydrogen bond donors at N1(a hydroxyalkyl or a methylaminoalkyl group) and C2 (a cyclohexanol group) positions, a series of novel benzimidazole derivatives were prepared, which exhibited selective JAK1 inhibitory activity (IC50against JAK1?=?0.08–0.15?μM; JAK1-selectivity?=?26–40 fold vs JAK2, 12–23 fold vs JAK3, and 38–54 fold vs Tyk2) along with significantly increased lipophilicity (3.3–15.8 times) as well as membrane permeability (6.3–12 times).
View MoreChongqing KonAo Health Co.,Ltd
Contact:13687578375
Address:wuhan hubei china
Zhejiang Genebest Pharmaceutical Co.,Ltd.
Contact:0086-571-63532866
Address:No.1 Jinboshi Rd Lishan Town Fuyang City Zhejiang Province China
Weifang Dongxing Chitosan Factory
website:http://dxchitosan.lookchem.com/
Contact:13475651157
Address:Weifang city ,shandong province
website:http://www.finerchem.com
Contact:+86-531-88989536
Address:New Material Industry Park, Jinan Ciyt, China
GUANGZHOUGRENSPSPORTS FACILITIES CO LTD
Contact:
Address:
Doi:10.1021/jacs.8b00809
(2018)Doi:10.1021/ie50336a016
()Doi:10.1002/oms.1210280708
(1993)Doi:10.1081/SCC-100000529
(2001)Doi:10.1002/chem.200802264
(2009)Doi:10.1016/S0960-894X(03)00591-2
(2003)